138 related articles for article (PubMed ID: 16541187)
1. Drug-induced hyperprolactinemia.
Bandyopadhyay P
Drugs Today (Barc); 2006 Feb; 42(2):103-19. PubMed ID: 16541187
[TBL] [Abstract][Full Text] [Related]
2. Drug-induced hyperprolactinemia.
Bandyopadhyay P
Timely Top Med Cardiovasc Dis; 2006 May; 10():E14. PubMed ID: 17066142
[TBL] [Abstract][Full Text] [Related]
3. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
4. Management of psychotropic-induced hyperprolactinemia.
Marken PA; Haykal RF; Fisher JN
Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
[TBL] [Abstract][Full Text] [Related]
5. Hyperprolactinemia associated with psychotropics--a review.
Madhusoodanan S; Parida S; Jimenez C
Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
[TBL] [Abstract][Full Text] [Related]
6. [Is the assessment of biological activity of prolactin essential in the diagnosis of hyperprolactinemia?].
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Pol Merkur Lekarski; 2010 May; 28(167):359-61. PubMed ID: 20568397
[TBL] [Abstract][Full Text] [Related]
7. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
Lu CC; Hsieh CJ
Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting.
García Cano AM; Rosillo M; Gómez Lozano A; Jiménez Mendiguchía L; Marchán Pinedo M; Rodríguez Torres A; Araujo-Castro M
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3239-3246. PubMed ID: 37910184
[TBL] [Abstract][Full Text] [Related]
9. Hyperprolactinemia.
Chahal J; Schlechte J
Pituitary; 2008; 11(2):141-6. PubMed ID: 18404389
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study.
Chen JX; Su YA; Bian QT; Wei LH; Zhang RZ; Liu YH; Correll C; Soares JC; Yang FD; Wang SL; Zhang XY
Psychoneuroendocrinology; 2015 Aug; 58():130-40. PubMed ID: 25981348
[TBL] [Abstract][Full Text] [Related]
11. Drugs and prolactin.
Molitch ME
Pituitary; 2008; 11(2):209-18. PubMed ID: 18404390
[TBL] [Abstract][Full Text] [Related]
12. Etiological diagnosis of hyperprolactinemia.
Cortet-Rudelli C; Sapin R; Bonneville JF; Brue T
Ann Endocrinol (Paris); 2007 Jun; 68(2-3):98-105. PubMed ID: 17524347
[TBL] [Abstract][Full Text] [Related]
13. Herbal medicine (Shakuyaku-kanzo-to) improves olanzapine-associated hyperprolactinemia: a case report.
Hori H; Yoshimura R; Katsuki A; Nakamura J
J Clin Psychopharmacol; 2013 Feb; 33(1):122-3. PubMed ID: 23288231
[No Abstract] [Full Text] [Related]
14. [Hyperprolactinemia].
König MP; Kopp P
Schweiz Med Wochenschr; 1986 Mar; 116(9):265-70. PubMed ID: 3952483
[TBL] [Abstract][Full Text] [Related]
15. A case of sibutramine-induced hyperprolactinemia.
Soares Leaes CG; Pereira-Lima JF; da Costa Oliveira M
Neuro Endocrinol Lett; 2011; 32(5):616-8. PubMed ID: 22167128
[TBL] [Abstract][Full Text] [Related]
16. Medication-induced hyperprolactinemia.
Molitch ME
Mayo Clin Proc; 2005 Aug; 80(8):1050-7. PubMed ID: 16092584
[TBL] [Abstract][Full Text] [Related]
17. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in the understanding of the pathophysiology and treatment of hyperprolactinemia.
Sarapura V; Schlaff WD
Curr Opin Obstet Gynecol; 1993 Jun; 5(3):360-7. PubMed ID: 8329652
[TBL] [Abstract][Full Text] [Related]
19. Clinical characterization of patients with macroprolactinemia and monomeric hyperprolactinemia.
Can M; Guven B; Atmaca H; Acıkgoz S; Mungan G
Kaohsiung J Med Sci; 2011 May; 27(5):173-6. PubMed ID: 21527183
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
Compton MT; Miller AH
Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
